Becton, Dickinson and Co (BD), Franklin Lakes, NJ, has been granted FDA emergency use authorization for a rapid, point-of-care, SARS-CoV-2 diagnostic for use with its BD Veritor Plus System. According to the company, the new assay delivers results in 15 minutes.
“This will be a game-changer for frontline healthcare workers and their patients to be able to access a quick diagnostic test for covid-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers, and doctors’ offices,” says Dave Hickey, president of Integrated Diagnostic Solutions for BD. “Such tests will also help communities be more informed and better prepared to help prevent new spikes and additional waves of covid-19 by enabling public health workers to quickly identify infectious individuals and trace their contacts.”
The BD Veritor System, which is slightly larger than a cell phone, is currently in use at more than 25,000 hospitals, clinician offices, urgent care centers, and retail pharmacies in all 50 states.
For more information, visit BD.